| 06th week of 2013 patent applcation highlights part 37 |
| Patent application number | Title | Published |
|---|
| 20130035297 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 2013-02-07 |
| 20130035298 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions. | 2013-02-07 |
| 20130035299 | ANTIMICROBIAL COMPOSITION BASED ON BOTANICAL EXTRACTS FROM OIL PALM VEGETATION LIQUOR - The present invention provides an antimicrobial composition comprising compounds extracted from the vegetation liquor of the palm oil milling process has been suggested. This composition is rich in antioxidants and exhibits enhanced antimicrobial activity and bactericidal effect against a number of micro-organisms. | 2013-02-07 |
| 20130035300 | METHOD OF USING POMEGRANATE EXTRACTS FOR INCREASING PROSTATE SPECIFIC ANTIGEN DOUBLING TIME - A method of increasing a prostate specific antigen (PSA) doubling time in treating a patient. A subject with rising serum PSA is selected. A composition is administered to the subject comprising a therapeutically effective amount of a pomegranate extract comprising a higher content of high molecular weight polyphenol compared to pomegranate juice from arils. The therapeutically effective amount increases a prostate specific antigen doubting time. The pomegranate extract is formed from an insoluble byproduct component obtained by placing pomegranate solids in an aqueous solution, heating the aqueous solution to between about 60° F. to about 210° F., adding at least one enzyme to the aqueous solution, and removing residual insoluble solid materials from the aqueous solution. | 2013-02-07 |
| 20130035301 | CDC7 KINASE INHIBITORS AND USES THEREOF - The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin. | 2013-02-07 |
| 20130035302 | USE OF YESSOTOXIN AND ANALOGUES AND DERIVATIVES THEREOF FOR TREATING AND/OR PREVENTING NEURODEGENERATIVE DISEASES LINKED TO TAU AND BETA AMYLOID - The present invention is in the field of biomedicine pharmaceutical chemistry. Specifically, it refers to the use of yessotoxin, its derivatives and analogues, for the preparation of a medicinal drug for the prevention and/or treatment of neurodegenerative diseases related to abnormal levels of Tau and β-amyloid proteins such as, for example, Alzheimer's disease. | 2013-02-07 |
| 20130035303 | COMPOSITIONS AND METHODS FOR CONTROL OF SAND FLIES AND OTHER BLOOD SUCKING INSECTS - The invention relates to a new rapid release oral formulation of fipronil or imidacloprid for the effective control of blood-sucking insect populations. Embodiments of the invention relate to their use by incorporation into a feed-through formulation that can be administered orally to host animals such as birds, goats, dogs, and cattle for the rapid effective control of blood sucking insects. The formulation is fast acting and the residue of the chemicals present in the feces serves as a larvacide, effectively controlling newly hatched larvae. | 2013-02-07 |
| 20130035304 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS - This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients. | 2013-02-07 |
| 20130035305 | USE OF AN ACTIVE INGREDIENT COMBINATION THAT CONTAINS HYDROXYSTILBENE FOR PREVENTING AND/OR TREATING DISEASES - The invention relates to the use of a combination of active ingredients, selected from resveratrol and piceatannol precursors and functional derivatives thereof, in addition to the use of the stereoisomeric forms of said ingredients, in the form of salts or phenol respectively, for producing an agent for the prevention and/or treatment of diseases, whose occurrence and/or progress is associated with an increased IL-6 serum level and/or whose occurrence and/or progress can be treated by a dose of a selective oestrogen receptor .beta. (ER-β) agonist. | 2013-02-07 |
| 20130035306 | PROCESS FOR PREPARING PURINE NUCLEOSIDES - The present invention provides for the preparation β-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein a blocked 2-deoxy-α-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of β to α-anomer is at least 99:1. | 2013-02-07 |
| 20130035307 | METHODS FOR TREATING OR PREVENTING THE SPREAD OF CANCER USING SEMI-SYNTHETIC GLYCOSAMINOGLYCOSAN ETHERS - Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEs”). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described. | 2013-02-07 |
| 20130035308 | COMPLEX COMBINING AN ORGANIC SILICON DERIVATIVE WITH HYALURONIC AND ACID CALIBRATED FRAGMENTS, FOR PREVENTIVE AND REPAIRING ACTION OF CUTANEOUS DAMAGES - The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): | 2013-02-07 |
| 20130035309 | OPHTHALMIC SEALANT COMPOSITION AND METHOD FOR USE - A polymeric hydrogel sealant specifically formulated to seal ophthalmic wounds is provided. The sealant is formed by mixing two aqueous solutions. The first aqueous solution comprises an oxidized dextran having a specific average molecular weight range and oxidation level and the second aqueous solution comprises a 4-arm polyethylene glycol having two primary amine groups at the end of substantially every arm. A kit and method for sealing an ophthalmic wound using the hydrogel sealant is also provided. | 2013-02-07 |
| 20130035310 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels - The present invention relates to piperidine and piperazine phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain. | 2013-02-07 |
| 20130035311 | PROCHELATORS FOR INHIBITING METAL-PROMOTED OXIDATIVE STRESS - The present invention provides compounds of Formula I along with compositions containing the same and methods of use thereof in treating oxidative stress. | 2013-02-07 |
| 20130035312 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS - This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. | 2013-02-07 |
| 20130035313 | Nucleoside Phosphonate Salts - The present invention relates to compounds and methods for treating viral diseases. Some compounds of the invention are described by Formula I: (I), wherein M | 2013-02-07 |
| 20130035314 | METHODS AND KITS FOR DETECTING RISK FACTORS FOR DEVELOPMENT OF JAW OSTEONECROSIS AND METHODS OF TREATMENT THEREOF - Methods of and kits for determining the pharmacogenetic, pharmacokinetic and cellular basis of bisphosphonate-induced osteonecrosis of the jaw (BONJ) involve associating particular proteins and particular single nucleotide polymorphisms with a risk for developing BONJ after receiving bisphosphonate treatment. Methods and kits for identifying the genetic basis for a patient's predisposition to BONJ, and methods of identifying patients who are prone to develop BONJ following bisphosphonate administration provide for the development of a tool for physicians to prescribe treatment protocols for BONJ patients based on the patients' genomes (“personal/tailored medicine”). A haplotype tagging SNP approach was used to analyze candidate genes involved in bone absorption and destruction and to examine the influence of genetic variants on the susceptibility of BONJ. Bone biomarkers of BONJ were examined using molecular cell techniques. The methods described herein can be used to identify differences in how patients are genetically predisposed to BONJ as well as genetic differences amongst patients that account for differences in how these patients clear bisphosphonate s from their systems. Determining such genetic differences provides for improved monitoring of the drugs used to treat BONJ, improved prevention of BONJ, and optimized treatment for patients having BONJ or predisposed to BOND. | 2013-02-07 |
| 20130035315 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY - Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans. | 2013-02-07 |
| 20130035316 | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN - This invention relates to the oral pharmaceutical composition of metformin and rosuvastatin. In detail, this invention comprising metformin, rosuvastatin, sustained release carriers and/or excipients reduces the side effects caused by statins and enhances safety, patients' convenience and compliance with its one-per-day dosage. In addition, regulation of an early effective blood concentration of the drug and maintenance of the drug's concentration at a steady level in vivo by a controlled-release can be advantageously used as a pharmaceutical composition for preventing and treating hyperlipidemia. | 2013-02-07 |
| 20130035317 | Di-Aspirin Derivatives - The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives. | 2013-02-07 |
| 20130035318 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY - Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: | 2013-02-07 |
| 20130035319 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS - A combination which comprises (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane. In the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid. | 2013-02-07 |
| 20130035320 | PYRROLIDINE DERIVATIVES - Novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series according to formulae (I) and (I′) are effective for the prevention and/or treatment of diseases in which the number, activity, and movement of inflammatory cells is implicated. | 2013-02-07 |
| 20130035321 | COMPOUNDS FOR THE TREATMENT OF OCULAR CANCER - In one aspect, the instant invention provides novel compounds and pharmaceutical compositions useful for treating proliferative diseases such as cancer. In another aspect, the invention provides methods of using certain compounds in the treatment of proliferative diseases such as cancer. In particular, the instant invention provides methods of treating ocular cancer (e.g., retinoblastoma) using intraarterial infusion to administer inventive compounds locally to the eye of a subject with an ocular cancer. | 2013-02-07 |
| 20130035322 | GOLD COMPLEXES - Gold (I) hydroxide complexes of the form Z-Au-OH and digold complexes of the form Z—Au-(μOH)—Au—Z where groups Z are two electron donors are provided. The groups Z may be carbenes, for example nitrogen containing heterocyclic carbenes (NHCs), phosphines or phosphites. The complexes can be used as catalysts, for example in reactions such as hydration of nitriles, skeletal arrangement of enynes, alkoxycyclisation of enynes, alkyne hydration, the Meyer-Shuster reaction, 3,3′ rearrangement of allylic acetates, cyclisation of propargylic acetates, Beckman rearrangements and hydroamination. The complexes can be used in medicine, for example in the treatment of cancer. | 2013-02-07 |
| 20130035323 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) | 2013-02-07 |
| 20130035324 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2013-02-07 |
| 20130035325 | KINASE INHIBITORS - Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed. | 2013-02-07 |
| 20130035326 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2013-02-07 |
| 20130035327 | Modulators of ATP-Binding Cassette Transporters - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2013-02-07 |
| 20130035328 | ANTIVIRAL COMPOUNDS AND METHODS - The invention relates to compounds having antiviral activity and methods utilizing the compounds to treat viral infections. | 2013-02-07 |
| 20130035329 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. | 2013-02-07 |
| 20130035330 | USE OF MELOXICAM FOR THE LONG-TERM TREATMENT OF MUSCULOSKELETAL DISORDERS IN CATS - The invention is directed to the use of a formulation comprising meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats. No negative effects on renal function occur following a treatment from 10 to 20 months or more. | 2013-02-07 |
| 20130035331 | THIAZOLE AND OXAZOLE KINASE INHIBITORS - The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors. | 2013-02-07 |
| 20130035332 | Substituted 1,3-Benzothiazol-2(3H)-Ones and [1,3]Thiazolo[5,4-B]Pyridin-2(IH)-Ones as Positive Allosteric Modulators of MGLUR2 - The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 2013-02-07 |
| 20130035333 | USE OF CINNABARINIC ACID AS A MODULATOR OF IMMUNE RESPONSES IN AUTOIMMUNE DISORDERS - The present invention provides compounds and methods for preventing and treating an immune disorder in a subject. | 2013-02-07 |
| 20130035334 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2013-02-07 |
| 20130035335 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS - Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders. | 2013-02-07 |
| 20130035336 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER - A combination of a CDK4/8 inhibitor and an mTOR inhibitor for the treatment of cancer. | 2013-02-07 |
| 20130035337 | FUSED BICYCLIC HETEROARYL DERIVATIVE - The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ. | 2013-02-07 |
| 20130035338 | EYELID TREATMENT - The current application is directed topical treatments that improve facial appearance by causing eyelids to naturally open more widely, or be more fully raised, as well as to treatment of ptosis and other eyelid-related conditions. These topical treatments include one or more of travoprost, dorzolamide hydrochloride, timolol maleate, unoprostone, latanoprost, bimatoprost, and related compounds currently used for treating glaucoma and ocular hypertension. | 2013-02-07 |
| 20130035339 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 2013-02-07 |
| 20130035340 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS - The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors. More particularly, the invention relates to the use of sGC stimulators and sGC activators in combination with PDE5 inhibitors for preparation of medicaments for the treatment of Cystic Fibrosis (CF). | 2013-02-07 |
| 20130035341 | MACROCYCLIC INTEGRASE INHIBITORS - Compound having formula I | 2013-02-07 |
| 20130035342 | Compound Suitable for the Treatment of Synucleopathies - The present invention relates to a compound of formula (I): Wherein R | 2013-02-07 |
| 20130035343 | COMBINATION OF ORGANIC COMPOUNDS - A pharmaceutical combination comprising 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one and at least one mTOR inhibitor and the pharmaceutical combination for use in treating or preventing a proliferative disease. | 2013-02-07 |
| 20130035344 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - The present invention relates to a solid pharmaceutical composition for oral administration, containing the following components (A) and (B): 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (compound a) or an acid addition salt thereof, and (B) citric acid. An improvement is achieved in the dissolubility of the compound a, which is useful as a therapeutic agent for hypercholesterolemia, arteriosclerosis, and the like. | 2013-02-07 |
| 20130035345 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF - The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion. | 2013-02-07 |
| 20130035346 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS - The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. | 2013-02-07 |
| 20130035347 | AROMATIC BYCYCLIC DERIVATIVES AS CXCR4 RECEPTOR MODULATORS - The present invention relates to novel aromatic bicyclic derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the CXCR4 receptor. | 2013-02-07 |
| 20130035348 | ANTIMETASTATIC COMPOUNDS - Screening methods for identifying compounds and compounds and pharmaceutical compositions for treating and preventing cancer are disclosed. The compounds affect signal transduction downstream of the MET receptor. | 2013-02-07 |
| 20130035349 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR - The present invention provides a novel pyrazolo[3,4-d]pyrimidin-4-one, specifically a derivative of 1-(pyridine-4-yl)-pyrazolo[3,4-d]pyrimidin-4-one. This compound is a kinase inhibitor that shows unexpected anti-proliferative activity against cells, including against tumor cells, and anti-tumor activity in xenograft tumor models. The compound or a suitable salt or prodrug thereof is useful for the treatment of individuals suffering from a cancer or another proliferative disorder or disease. | 2013-02-07 |
| 20130035350 | Novel Quinazoline Derivatives - This disclosure concerns novel quinazoline compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful anticancer agents, especially in inhibiting the function of the EGF receptor tyrosine kinases, HER1 tyrosine kinase, and HER2 tyrosine kinase. Thus, the disclosure also concerns a method of treating hyperproliferative diseases or conditions, such as various cancers and benign prostate hyperplasia (BPH), by use of these novel compounds or a composition comprising such novel compounds. | 2013-02-07 |
| 20130035351 | Oximes For Treatment Of Peripheral And Central Nervous System Exposure To Acetyl Cholinesterase Inhibitors - The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates. | 2013-02-07 |
| 20130035352 | GABA CONJUGATES AND METHODS OF USE THEREOF - In one aspect, the present invention provides a composition of a covalent conjugate of a GABA analog with a drug. In another aspect, the present invention provides methods for treating pain and neurological disorders using the conjugates of GABA analogs. | 2013-02-07 |
| 20130035353 | DRUGS FOR THE TREATMENT OF SARCOGLYCANOPATHIES - Inhibitors of the endoplasmic reticulum associated degradation (ERAD) pathway, particularly inhibitors of mannosidase I, are used for the preparation of a medicinal product intended to treat sarcoglycanopathies. | 2013-02-07 |
| 20130035354 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS - The present invention provides a compound of formula I; | 2013-02-07 |
| 20130035355 | PRASUGREL IN MICRONIZED, CRYSTALLINE FORM AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention relates to Prasugrel or a pharmaceutically acceptable salt thereof, compositions containing said active ingredient as well as pharmaceutical compositions containing said active ingredient or a composition containing said active ingredient. The present invention further relates to methods for the preparation of the novel compositions. | 2013-02-07 |
| 20130035356 | CRYSTAL OF DIAMINE DERIVATIVE AND METHOD OF PRODUCING SAME - An object of the present invention is to provide a novel crystal form of a compound that has an inhibitory effect on activated blood coagulation factor X and is useful as a pharmaceutical compound for prevention and/or treatment of thrombotic and/or embolic diseases. The present invention provides a novel crystal form of N | 2013-02-07 |
| 20130035357 | Compositions and Methods for Preventing Joint Destruction in Osteoarthritis - The present invention is methods for inhibiting collagen destruction in joints of osteoarthritis patients. The methods are based on use of rexinoid compounds, in particular bexarotene, and their activity to inhibit synthesis of matrix metalloproteinases (MMPs) in affected tissue. | 2013-02-07 |
| 20130035358 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors - There is provided compounds of formula I, | 2013-02-07 |
| 20130035359 | COMPOSITIONS CONTAINING AROMATIC ALDEHYDES AND THEIR USE IN TREATMENTS - Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals. | 2013-02-07 |
| 20130035360 | NOVEL WATER SOLUBLE FUROXAN DERIVATIVES HAVING ANTITUMOR ACTIVITY - Water soluble compounds having a furoxan structure which are capable of inhibiting metabolic pathways involved in the development of the tumours are provided. The use of such compounds as a medicament in the therapy of the tumours and as an adjuvant in the immunotherapy protocols against neoplasms is also described. | 2013-02-07 |
| 20130035361 | USE OF ERGOTHIONEINE AS A PRESERVATIVE IN FOODS AND BEVERAGES - The invention relates to the novel use of ergothioneine and preferably, L ergothioneine, as a nutritional additive and preservative in foods, medicines, and/or beverages. According to the invention, the powerful antioxidant ergothioneine was found to be very stable over time in and to have no deleterious effects on taste or consistency of food and beverages even when stored, over a period of several years. In a preferred embodiment, ergothioneine may be used as a replacement for all or part of the antimicrobial/preservative sulfur dioxide or other sulfites traditionally used in the wine making process. | 2013-02-07 |
| 20130035362 | Stable Anti-inflammatory Solutions for Injection - The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline. | 2013-02-07 |
| 20130035363 | Thalidomide Analogs - Thalidomide analogs that modulate tumor necrosis factor alpha (TNFα) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs. | 2013-02-07 |
| 20130035364 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE - Compounds of general formula I: | 2013-02-07 |
| 20130035365 | Anti-sense oligonucleotides targeted against exon 9 of IL-23R alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases - The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23Rα gene. Exon 9 skipping of the IL23Rα gene ultimately causes specific induction of a novel soluble truncated IL-23Rα (Δ9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a Δ9 protein which inhibits IL-23R-mediated cell signaling. More particularly, Δ9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease. | 2013-02-07 |
| 20130035366 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions. | 2013-02-07 |
| 20130035367 | ANTISENSE OLIGONUCLEOTIDES THAT TARGET A CRYPTIC SPLICE SITE IN USH1C AS A THERAPEUTIC FOR USHER SYNDROME - The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript. | 2013-02-07 |
| 20130035368 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS - The invention relates to siRNA compounds comprising one non-nucleotide moiety covalently attached to at least one of the sense or antisense strands to down-regulate the expression of human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the target genes and/or symptoms associated with such diseases or conditions. | 2013-02-07 |
| 20130035369 | DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION - The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. | 2013-02-07 |
| 20130035370 | COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION - Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds. | 2013-02-07 |
| 20130035371 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE - This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene. | 2013-02-07 |
| 20130035372 | TREATMENT OF COLONY-STIMULATING FACTOR 3 (CSF3) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO CSF3 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Colony-stimulating factor 3 (CSF3), in particular, by targeting natural antisense polynucleotides of Colony-stimulating factor 3 (CSF3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CSF3. | 2013-02-07 |
| 20130035373 | TREATMENT OF FIBROBLAST GROWTH FACTOR 21 (FGF21) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO FGF21 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Fibroblast growth factor 21 (FGF21), in particular, by targeting natural antisense polynucleotides of Fibroblast growth factor 21 (FGF21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FGF21. | 2013-02-07 |
| 20130035374 | MicroRNA induction of pluripotential stem cells and uses thereof - Compositions and methods for inducing the formation of an induced pluripotential stem (iPS) cell from a somatic cell are disclosed. The compositions comprise miR 302-367 cluster and valproic acid. Further disclosed are methods for treatment of a disease or condition in a subject through the use of the compositions. | 2013-02-07 |
| 20130035375 | Gene re-cycling - Through ecological re-cycling, plants take up the nutrients from the cadavers. But it is not understood whether the plant roots can take the nutrients and the genes of the dead plants and cadavers, to develop into a transgenic plants. | 2013-02-07 |
| 20130035376 | MCP-1 binding nucleic acids - The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115 | 2013-02-07 |
| 20130035377 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASES LSD1 AND/OR LSD2 - Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong to the structural formula (I) wherein A and R | 2013-02-07 |
| 20130035378 | FILM DELIVERY SYSTEM FOR TETRAHYDROLIPSTATIN - The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including tetrahydrolipstatin, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided | 2013-02-07 |
| 20130035379 | Compositions for Inhibiting Protine-Directed Protein Kinase Fa/Glycogen Synthesis Kinase 3 Alpha and Use Thereof - The invention provides a composition for inhibiting proline-directed protein kinase F | 2013-02-07 |
| 20130035380 | PROCESS FOR SELECTIVE EXTRACTION OF BIOACTIVE AND BIOAVAILABLE CINNAMON POLYPHENOLS AND PROCYANIDIN OLIGOMERS AND A STABLE COMPOSITION THEREOF - The present invention relates to a process for selective extraction of bioactive and bioavailable cinnamon polyphenols and procyanidin oligomers of the type A and type B, of more than 90% purity as gallic acid equivalent which comprises the steps of removing the organic solvent from the extract to produce the free flowing oleoresin and drying of the residue under optimized conditions to produce a polyphenol and procyanidin Type A & B polymer rich solid which on subsequent extraction with water or with mixture of water and acetone or water and lower alcohol and further evaporation to a solid content of not more than 6% and subsequent chromatographic separation to obtain fractions containing procyanidin type A and B polymers free of coumarins and cinnamaldehyde. The present invention also relates to stable composition comprising cinnamon polyphenol rich powder for delivering maximum bioactivity upon oral administration. | 2013-02-07 |
| 20130035381 | VIRUS-INACTIVATING COMPOSITION CONTAINING LOW-MOLECULAR WEIGHT COMPOUND AND ARGININE - The invention provides a virus-inactivating composition with pH of 3.8 to 5.5, containing (A) 0.02 to 0.3 M arginine and (B) a component such as 0.01 to 10 mM flavonoid, polyphenol, or ascorbic acid derivative, 0.005 to 5 mass % of an arginine derivative, and 0.1 to 2.5 mass % of an extract solution of natural product. | 2013-02-07 |
| 20130035382 | Anti-Viral Compounds - Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway. | 2013-02-07 |
| 20130035383 | LIQUID/LIQUID EXTRACTION - The invention relates to a method for the extraction of all unsaponifiable fraction contained in a vegetable oil, an oil originating from a micro-organism or a vegetable butter or in a co-product from the vegetable oil refining industry, such as deodorisation discharge. The method includes at least: A) a step comprising the transformation of the aforementioned oils, butter or co-product from the vegetable oil refining industry or oils originating from micro-organisms into a hydro-alcoholic solution by means of, in particular, a step selected from saponification and esterification steps; B) a step comprising the extraction of the hydro-alcoholic solution in which the fatty fraction is separated from the unsaponitiable fraction by means of liquid/liquid extraction; and C) an optional step comprising the purification of the unsaponiable fraction, selected from the group containing crystallisation and liquid/liquid extraction steps. According to the invention, at least one step from the liquid/liquid extraction steps in step B, the crystallisation steps in step C and the liquid/liquid extraction steps in step C is performed using a first solvent system containing a concentration of solvent selected from among: fluorinated aromatic solvents, particularly trifluorotoluene (BTF) and hexalluorobenzene (BHF); tert-butyl ethers, particularly 2-ethoxy-2-methylpropane, also known as ethyl-tert-butyl-ether (ETU); solvents comprising at least one silicon atom, particularly hexamethyldisiloxane (HMDS) and tertramethylsilane (TMS); methyl-tetrahydrofuran (MeTHF); and mixtures thereof, representing at least 50 vol.-% in relation to the total volume of the solvent system. The invention also relates to the fractions obtained using this method and to compositions containing said fractions. | 2013-02-07 |
| 20130035384 | ORALLY DISPERSIBLE TABLET - The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture. | 2013-02-07 |
| 20130035385 | ORALLY DISPERSIBLE TABLET - The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture. | 2013-02-07 |
| 20130035386 | BIS[THIOHYDRAZIDE AMIDE] COMPOUNDS FOR TREATING LEUKEMIA - Certain bis[thio-hydrazide amide]-related compounds are found to be surprisingly effective at treating with leukemia, e.g., acute myeloid leukemia (AML). Methods of treating a subject with AML including administering bis[thio-hydrazide amide]-related compounds described herein, are disclosed. | 2013-02-07 |
| 20130035387 | SARMS AND METHOD OF USE THEREOF - This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds. | 2013-02-07 |
| 20130035388 | Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex - This patent pertains to selective inhibition of assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by the membrane attack complex. These diseases include, but are not limited to, Alzheimer disease, age related macular degeneration, and atherosclerosis. | 2013-02-07 |
| 20130035389 | METHODS FOR TREATING MYELODYSPLASTIC SYNDROME WITH EZATIOSTAT - This invention relates to methods, assays, devices and systems for identifying patients having a myelodysplastic syndrome for treatment with ezatiostat or a salt thereof, or evaluating the patient's response possibility to the treatment by measuring and evaluating the patient's gene expression profile. This invention also relates to methods of treating myelodysplastic syndromes. | 2013-02-07 |
| 20130035390 | TREATMENT OF MULTIPLE SCLEROSIS - Disclosed are methods for treating multiple sclerosis patients that entail co-administration of effective amounts of a Ras antagonist which is farnesylthiosalicylic acid or an analog thereof, and a second active agent selected from glatiramer acetate, laquinimod and combinations thereof. Therapeutic compositions and methods of making them are also disclosed. | 2013-02-07 |
| 20130035391 | Felbinac-Containing Transdermally Absorbable Preparation - An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster. | 2013-02-07 |
| 20130035392 | Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex - It pertains to selective inhibition of C3 convertase of the alternative pathway of complement as well as the previously claimed assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by C3 convertase activation of the alternative complement pathway, or the membrane attack complex, or both pathways. These diseases include, but are not limited to, paroxysmal nocturnal hemoglobinemia, rheumatoid arthritis, multiple sclerosis, malaria infection, Alzheimer disease, age related macular degeneration, and atherosclerosis. | 2013-02-07 |
| 20130035393 | METHOD FOR TREATING SCHIZOPHRENIA - The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative. | 2013-02-07 |
| 20130035394 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making - A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described. | 2013-02-07 |
| 20130035395 | WATER-BASED COSMETIC AND MANUFACTURING METHOD THEREOF - A water-based cosmetic that includes: (A) ceramidic compound-containing particles that include a ceramidic compound and that are dispersed as an oil phase in an aqueous phase; (B) a fatty acid component composed of at least one selected from the group consisting of fatty acids and fatty acid salts; and (C) a polyhydric alcohol component that includes a first polyhydric alcohol having an IOB of 2.2 or more and a total content in the composition of from 3% by mass to 20% by mass, and a second polyhydric alcohol having an IOB of 2.0 or less and a total content in the composition of 0% by mass or not more than 3% by mass, wherein a total content of surfactant in the composition is 0% by mass or not more than 1% by mass, and a total mass of ceramidic compound in the composition is at least 3.0 times a total mass of the fatty acid component in the composition. | 2013-02-07 |
| 20130035396 | ANTIMICROBIAL CLEANSING COMPOSITIONS - Antimicrobial cleansing compositions are disclosed. The cleansing compositions include thin liquid/foaming compositions and gels. The antimicrobial cleansing compositions are effective antimicrobials and safe for everyday use. | 2013-02-07 |
